Category Press Releases

Nucleus RadioPharma Boosts Radiopharmaceutical R&D and Production to Address U.S. Supply Chain Challenges

Nucleus RadioPharma announced the development of two new facilities, totaling over 100,000 square feet, in Mesa, Arizona, and Spring House, Pennsylvania. These state-of-the-art sites will integrate research, development, and commercial production under one roof, providing significant time and scale advantages…

Read MoreNucleus RadioPharma Boosts Radiopharmaceutical R&D and Production to Address U.S. Supply Chain Challenges

Nuclidium Announces First Patient Imaging in Phase 1 Trial of 61Cu-based Radiotracer for PSMA-positive Prostate Cancer

NUCLIDIUM today announced the successful imaging of the first patient in a Phase 1 clinical trial evaluating its radiotracer candidate as a safe and effective diagnostic and disease-staging tool in prostate cancer patients. The candidate, 61Cu-NuriPro™ (61Cu-NODAGA-PSMA I&T), is part…

Read MoreNuclidium Announces First Patient Imaging in Phase 1 Trial of 61Cu-based Radiotracer for PSMA-positive Prostate Cancer

Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and its affiliate CyanVac LLC, today announced the presentation of…

Read MoreBlue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress

Ferring Pharmaceuticals Showcases Commitment to Fertility Care at 2024 ASRM Congress

Ferring Pharmaceuticals will present new research across four abstracts at the 2024 American Society for Reproductive Medicine (ASRM) Congress, taking place from October 19-23 in Denver, Colorado, and online. The abstracts include two oral and two poster presentations, reflecting Ferring’s…

Read MoreFerring Pharmaceuticals Showcases Commitment to Fertility Care at 2024 ASRM Congress

Vertex to Present Phase 3 Data on Suzetrigine as a Pain Signal Inhibitor at ASA Meeting

Vertex Pharmaceuticals (Nasdaq: VRTX) announced that it will present Phase 3 data on suzetrigine, an investigational oral NaV1.8 pain signal inhibitor for moderate-to-severe acute pain, at the American Society of Anesthesiologists (ASA) annual meeting from October 18-22, 2024, in Philadelphia,…

Read MoreVertex to Present Phase 3 Data on Suzetrigine as a Pain Signal Inhibitor at ASA Meeting

Scholar Rock Announces New Employee Inducement Grants Under Nasdaq Rule 5635(c)(4)

Scholar Rock Grants Inducement Equity Awards to New Employees Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases influenced by protein growth factors, has announced the…

Read MoreScholar Rock Announces New Employee Inducement Grants Under Nasdaq Rule 5635(c)(4)

GE HealthCare, Foundations Pledge $1M to Enhance Health Outcomes in Milwaukee

The “Powering Milwaukee Forward” initiative is set to enhance access to essential services and maternal healthcare in vulnerable communities across Milwaukee. Launched by GE HealthCare (Nasdaq: GEHC), the GE HealthCare Foundation, and the Charles Antetokounmpo Family Foundation (CAFF), this philanthropic…

Read MoreGE HealthCare, Foundations Pledge $1M to Enhance Health Outcomes in Milwaukee

Ferring Pharmaceuticals Showcases Commitment to Fertility Care at 2024 ASRM Congress

Ferring Pharmaceuticals Showcases Commitment to Advancing Fertility Care at 2024 ASRM Congress Ferring Pharmaceuticals will present new data from four abstracts at the 2024 American Society for Reproductive Medicine (ASRM) Congress, taking place from October 19-23 in Denver, Colorado, and…

Read MoreFerring Pharmaceuticals Showcases Commitment to Fertility Care at 2024 ASRM Congress

Actineer, the Joint Venture of ITM and CNL, Launches Actinium-225 Production

Successful Cyclotron Irradiation of Ra-226 Paves the Way for Actineer’s Large-Scale Ac-225 Production for Cancer Treatments Actineer, the joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has achieved a significant milestone by successfully producing Actinium-225 (Ac-225) through the…

Read MoreActineer, the Joint Venture of ITM and CNL, Launches Actinium-225 Production

Xaira Therapeutics Names Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer

Xaira Therapeutics Appoints Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer Xaira Therapeutics, an integrated biotechnology firm focused on leveraging AI to transform drug discovery and development, has announced the appointments of Dr. Debbie…

Read MoreXaira Therapeutics Names Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer